Search

Your search keyword '"Seliger, B"' showing total 657 results
Start Over Author "Seliger, B"
657 results on '"Seliger, B"'

3. Development of an immune therapeutic approach against SARS-CoV-2

Author

Drewitz, L., Kegler, A., (0000-0003-4916-3794) Laube, M., Ziehr, H., Heine, M., Moreira-Soto, A., Kühne, A., Felix Drexler, J., Seliger, B., (0000-0002-1285-5052) Arndt, C., (0000-0002-8733-4286) Bergmann, R., (0000-0001-5099-2448) Feldmann, A., (0000-0002-8029-5755) Bachmann, M., Drewitz, L., Kegler, A., (0000-0003-4916-3794) Laube, M., Ziehr, H., Heine, M., Moreira-Soto, A., Kühne, A., Felix Drexler, J., Seliger, B., (0000-0002-1285-5052) Arndt, C., (0000-0002-8733-4286) Bergmann, R., (0000-0001-5099-2448) Feldmann, A., and (0000-0002-8029-5755) Bachmann, M.

Abstract

Immunotherapies are already successfully used for cancer treatment. In our lab two modular platform technologies were developed which demonstrated high success against various types of malignant cells: the universal chimeric antigen receptor (UniCAR) system, and the bispecific antibody (bsAb) based UniMAB system. Both approaches have the aim to recruit T cells to kill the malignant cells carrying a tumor associated antigen (TAA) on their surface. In the first case, UniCAR modified T cells are linked via a TAA specific target module (TM) to cancer cells. In the case of the UniMAB system, natural T cells are recruited to cancer cells via a TAA specific TM and a bsAb based effector module (EM) which binds to CD3 of T cells and to an epitope tag of the TM. In both cases, an immune complex is formed leading to T cell activation and tumor cell elimination. Most importantly, the T cell activation is dependent on the cross-linkage of T cells and tumor cells via the TM or TM/EM complex. Thus, T cell activation is steerable which increases the safety of these approaches. With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to millions of deaths worldwide, we aimed to apply the UniCAR and UniMAB technology against SARS-CoV-2 and virus infected cells as novel immunotherapeutic treatment approach. For this purpose, we designed two TMs binding to the receptor binding domain (RBD) of SARS-CoV-2. The first TM is based on a single chain fragment variable (scFv) with specificity for RBD, whereas the second one contains the extracellular domain of the human ACE2 receptor which is the entry receptor of SARS-CoV-2. Both TMs were able to efficiently recruit either UniCAR T cells or, in combination with the EM of the UniMAB system, natural T cells to efficiently kill human cells having the RBD of SARS-CoV-2 on their surface. Remarkably, the ACE2-Mb-TM is additionally able to block RBD/ACE2 interaction and potently neutralizes pseudo- as well as live S

Published
2023

4. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells

Author

Kegler, A., Drewitz, L., (0000-0002-1285-5052) Arndt, C., Daglar, C., Rodrigues Loureiro, L. R., Mitwasi, N., (0000-0002-0646-5808) Neuber, C., González Soto, K. E., Bartsch, T., (0000-0003-1010-2791) Baraban, L., Ziehr, H., Heine, M., Nieter, A., Moreira-Soto, A., Kühne, A., Drexler, J. F., Seliger, B., (0000-0003-4916-3794) Laube, M., Máthé, D., Pályi, B., Hajdrik, P., Forgách, L., Kis, Z., Szigeti, K., (0000-0002-8733-4286) Bergmann, R., (0000-0001-5099-2448) Feldmann, A., (0000-0002-8029-5755) Bachmann, M., Kegler, A., Drewitz, L., (0000-0002-1285-5052) Arndt, C., Daglar, C., Rodrigues Loureiro, L. R., Mitwasi, N., (0000-0002-0646-5808) Neuber, C., González Soto, K. E., Bartsch, T., (0000-0003-1010-2791) Baraban, L., Ziehr, H., Heine, M., Nieter, A., Moreira-Soto, A., Kühne, A., Drexler, J. F., Seliger, B., (0000-0003-4916-3794) Laube, M., Máthé, D., Pályi, B., Hajdrik, P., Forgách, L., Kis, Z., Szigeti, K., (0000-0002-8733-4286) Bergmann, R., (0000-0001-5099-2448) Feldmann, A., and (0000-0002-8029-5755) Bachmann, M.

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options, which can win the race against new emerging variants of concern. Here, we describe a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor ACE2 and provide experimental evidence that it cannot only be used for (i) neutralization of SARS-CoV-2 in vitro and in SARS-CoV-2 infected animal models, but also for (ii) clearance of virus infected cells. For the latter purpose, we equipped the ACE2 decoy with an epitope tag. Thereby, we converted it to an adapter molecule which we successfully applied in the modular platforms UniMAB and UniCAR for retargeting of either unmodified or universal chimeric antigen receptor modified immune effector cells. Our results pave the way for a clinical application of this novel ACE2 decoy, which will clearly improve COVID-19 treatment.

Published
2023

5. Development Of A Novel ACE2 Decoy For Both SARS-CoV-2 Variant Neutralization And Infected Cell Elimination Via Unmodified Or CAR Modified Immune Cells

Author

Drewitz, L., Kegler, A., (0000-0002-1285-5052) Arndt, C., Daglar, C., Rodrigues Loureiro, L. R., Mitwasi, N., (0000-0002-0646-5808) Neuber, C., González Soto, K. E., Bartsch, T., (0000-0003-1010-2791) Baraban, L., Ziehr, H., Heine, M., Nieter, A., Moreira-Soto, A., Kühne, A., Drexler, J. F., Seliger, B., (0000-0003-4916-3794) Laube, M., Máthé, D., Pályi, B., Hajdrik, P., Forgách, L., Kis, Z., Sziget, K., (0000-0002-8733-4286) Bergmann, R., (0000-0001-5099-2448) Feldmann, A., (0000-0002-8029-5755) Bachmann, M., Drewitz, L., Kegler, A., (0000-0002-1285-5052) Arndt, C., Daglar, C., Rodrigues Loureiro, L. R., Mitwasi, N., (0000-0002-0646-5808) Neuber, C., González Soto, K. E., Bartsch, T., (0000-0003-1010-2791) Baraban, L., Ziehr, H., Heine, M., Nieter, A., Moreira-Soto, A., Kühne, A., Drexler, J. F., Seliger, B., (0000-0003-4916-3794) Laube, M., Máthé, D., Pályi, B., Hajdrik, P., Forgách, L., Kis, Z., Sziget, K., (0000-0002-8733-4286) Bergmann, R., (0000-0001-5099-2448) Feldmann, A., and (0000-0002-8029-5755) Bachmann, M.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic with millions of infections and deaths worldwide and devastating impact on global economy. Up to now, vaccines and monoclonal antibody (mAb) therapies lack to provide a long-lasting protection against rapidly evolving new emerging SARS-CoV-2 variants. Thus, novel therapeutic options are pressingly needed especially for immunocompromised patients and/or patients with high risk for developing a severe coronavirus disease 2019 (COVID-19). In that regard, we developed a novel immunotherapeutic drug based on the SARS-CoV-2 entry receptor angiotensin-converting enzyme 2 (ACE2). This ACE2 decoy potently binds to the SARS-CoV-2 receptor binding domain (RBD), neutralizes SARS-CoV-2 as well as the Delta and Omicron variant and protects hamsters from a SARS-CoV-2 infection. To additionally use this ACE2 decoy for elimination of virus infected cells, we equipped it with an epitope tag. Thus, it can be applied as adapter molecule in the modular platform technologies UniMAB and UniCAR, which already demonstrated great success in the setting of malignant diseases. As adapter molecule the ACE2 decoy is able to efficiently recruit either universal chimeric antigen receptor (UniCAR) modified T cells or, in combination with an anti-peptide epitope-anti-CD3 bispecific Ab of the UniMAB system, unmodified T cells to efficiently kill SARS-CoV-2 RBD expressing human cells. Taken together, the ACE2 decoy represents a very promising immunotherapeutic drug for both SARS-CoV-2 variant neutralization and infected cell killing via the UniMAB and UniCAR system and might, therefore, clearly improve the treatment of COVID-19 patients.

Published
2023

7. 151P Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts

Author

Galas, K., primary, Gleitsmann, M., additional, Rey, J., additional, Solbach, C., additional, Witzel, I., additional, Seliger, B., additional, Karn, T., additional, Schmatloch, S., additional, Schneeweiss, A., additional, Sinn, B.V., additional, Fehm, T.N., additional, Denkert, C., additional, Litmeyer, A-S., additional, Jank, P., additional, Furlanetto, J., additional, Ortmann, O., additional, Van Mackelenbergh, M.T., additional, Nekljudova, V., additional, and Loibl, S., additional

Published
2022
Full Text
View/download PDF

9. In vitro models as tools for screening treatment options of head and neck cancer

Author

Seliger, B. (Barbara), Al-Samadi, A. (Ahmed), Yang, B. (Bo), Salo, T. (Tuula), Wickenhauser, C. (Claudia), Seliger, B. (Barbara), Al-Samadi, A. (Ahmed), Yang, B. (Bo), Salo, T. (Tuula), and Wickenhauser, C. (Claudia)

Abstract

Various in vitro models using primary and established 2- and 3-dimensional cultures, multicellular tumor spheroids, standardized tumor slice cultures, tumor organoids, and microfluidic systems obtained from tumor lesions/biopsies of head and neck cancer (HNC) have been employed for exploring and monitoring treatment options. All of these in vitro models are to a different degree able to capture the diversity of tumors, recapitulate the disease genetically, histologically, and functionally and retain their tumorigenic potential upon xenotransplantation. The models were used for the characterization of the malignant features of the tumors and for in vitro screens of drugs approved for the treatment of HNC, including chemotherapy and radiotherapy as well as recently developed targeted therapies and immunotherapies, or for novel treatments not yet licensed for these tumor entities. The implementation of the best suitable model will enlarge our knowledge of the oncogenic properties of HNC, expand the drug repertoire and help to develop individually tailored treatment strategies resulting in the translation of these findings into the clinic. This review summarizes the different approaches using preclinical in vitro systems with their advantages and disadvantages and their implementation as preclinical platforms to predict disease course, evaluate biomarkers and test therapy efficacy.

Published
2022

10. Induction of pulmonary HLA-G expression by SARS-CoV-2 infection

Author

Seliger, B., Jasinski-Bergner, S., Masssa, C., Müller, A., Biehl, K., Yang, B., (0000-0002-8029-5755) Bachmann, M., Jonigk, D., Eichhorn, P., Hartmann, A., Wickenhauser, C., Bauer, M., Seliger, B., Jasinski-Bergner, S., Masssa, C., Müller, A., Biehl, K., Yang, B., (0000-0002-8029-5755) Bachmann, M., Jonigk, D., Eichhorn, P., Hartmann, A., Wickenhauser, C., and Bauer, M.

Abstract

The non-classical human leukocyte antigen (HLA)-G exerts immune-suppressive properties modulating both NK and T cell responses. While it is physiologically expressed at the maternal–fetal interface and in immune-privileged organs, HLA-G expression is found in tumors and in virus-infected cells. So far, there exists little information about the role of HLA-G and its interplay with immune cells in biopsies, surgical specimen or autopsy tissues of lung, kidney and/or heart muscle from SARS-CoV-2-infected patients compared to control tissues. Heterogeneous, but higher HLA-G protein expression levels were detected in lung alveolar epithelial cells of SARS-CoV-2-infected patients compared to lung epithelial cells from influenza-infected patients, but not in other organs or lung epithelia from non-viral-infected patients, which was not accompanied by high levels of SARS-CoV-2 nucleocapsid antigen and spike protein, but inversely correlated to the HLA-G-specific miRNA expression. High HLA-G expression levels not only in SARS-CoV-2-, but also in influenza-infected lung tissues were associated with a high frequency of tissue-infiltrating immune cells, but low numbers of CD8+ cells and an altered expression of hyperactivation and exhaustion markers in the lung epithelia combined with changes in the spatial distribution of macrophages and T cells. Thus, our data provide evidence for an involvement of HLA-G and HLA-G-specific miRNAs in immune escape and as suitable therapeutic targets for the treatment of SARS-CoV-2 infections.

Published
2022

12. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation

Author

Maio M., Lahn M., Di Giacomo A. M., Covre A., Calabro L., Ibrahim R., Fox B., Abrignani S., Paola A., Anichini A., Ardizzoni A., Gregorio A., Azab M., Ballas M., Barberis M., Bayless N. L., Bell B., Bifarini A., Blank C., Brodin P., Camerini R., Ennio C., Ceccarelli M., Francesca C., Connolly J., Sandra C., Cornelissen R., Eggermont A., Eid J., Fajgenbaum D., Ferretti E., Ferrone S., Finotello F., Flaherty K., Ester F., Elisabetta F., Fridman C. S., Fridman W. H., Garcia P., Gherardini P. F., Goonewardene A., Hacking G., Heller K., Hulett T. W., Michael I., Jacobson D., Janek M., Joho S., Keer H., Kleif S., Kotecha N., Kotter M., Krogan N., Lanzavecchia A., Locatelli F., Lollini P. -L., Mantovani A., Melacarne A., Melillo G., Menden M., Minerva D., Moretta L., Namouni F., Natali P. G., Necchi A., Nistico P., Cosimo P., Giuseppe P., Pardoll D., Paz-Ares L., Plessala K., Peters S., Prins R. M., Provendier O., Rappuoli R., Rescigno M., Ruettinger D., Seliger B., Sette A., Luca S., Spasic M., Tortora G., Trajanoski Z., Tunici P., Vitale C., Wigginton J., Yadav M., Yu H., Maio, Michele, Lahn, Michael, Di Giacomo, Anna Maria, Covre, Alessia, Calabrò, Luana, Ibrahim, Ramy, Fox, Bernard, Siena Think Tank, Lollini, Pier-Luigi, Pulmonary Medicine, Maio, M., Lahn, M., Di Giacomo, A. M., Covre, A., Calabro, L., Ibrahim, R., Fox, B., Abrignani, S., Paola, A., Anichini, A., Ardizzoni, A., Gregorio, A., Azab, M., Ballas, M., Barberis, M., Bayless, N. L., Bell, B., Bifarini, A., Blank, C., Brodin, P., Camerini, R., Ennio, C., Ceccarelli, M., Francesca, C., Connolly, J., Sandra, C., Cornelissen, R., Eggermont, A., Eid, J., Fajgenbaum, D., Ferretti, E., Ferrone, S., Finotello, F., Flaherty, K., Ester, F., Elisabetta, F., Fridman, C. S., Fridman, W. H., Garcia, P., Gherardini, P. F., Goonewardene, A., Hacking, G., Heller, K., Hulett, T. W., Michael, I., Jacobson, D., Janek, M., Joho, S., Keer, H., Kleif, S., Kotecha, N., Kotter, M., Krogan, N., Lanzavecchia, A., Locatelli, F., Lollini, P. -L., Mantovani, A., Melacarne, A., Melillo, G., Menden, M., Minerva, D., Moretta, L., Namouni, F., Natali, P. G., Necchi, A., Nistico, P., Cosimo, P., Giuseppe, P., Pardoll, D., Paz-Ares, L., Plessala, K., Peters, S., Prins, R. M., Provendier, O., Rappuoli, R., Rescigno, M., Ruettinger, D., Seliger, B., Sette, A., Luca, S., Spasic, M., Tortora, G., Trajanoski, Z., Tunici, P., Vitale, C., Wigginton, J., Yadav, M., and Yu, H.

Subjects
0301 basic medicine, Oncology, Mesothelioma, Cancer Research, Artificial intelligence, Research areas, medicine.medical_treatment, Corona virus disease 19 (COVID-19), Glioblastoma, Immunotherapy, Melanoma, Novel treatments, PD-L1, PD1, Antibodies, Monoclonal, COVID-19, Humans, Immunity, Italy, Medical Oncology, Neoplasms, Meeting Report, 0302 clinical medicine, Monoclonal, RC254-282, Foundation (evidence), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunotherapy, Novel treatments, PD1, PD-L1, Melanoma, Mesothelioma, Artificial intelligence, Glioblastoma, Corona virus disease 19 (COVID-19), 030220 oncology & carcinogenesis, Non small cell, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Antibodies, NO, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Novel treatment, Tumor microenvironment, business.industry, Cancer, medicine.disease, 030104 developmental biology, business
Abstract

Background The yearly Think Tank Meeting of the Italian Network for Tumor Biotherapy (NIBIT) Foundation, brings together in Siena, Tuscany (Italy), experts in immuno-oncology to review the learnings from current immunotherapy treatments, and to propose new pre-clinical and clinical investigations in selected research areas. Main While immunotherapies in non-small cell lung cancer and melanoma led to practice changing therapies, the same therapies had only modest benefit for patients with other malignancies, such as mesothelioma and glioblastoma. One way to improve on current immunotherapies is to alter the sequence of each combination agent. Matching the immunotherapy to the host’s immune response may thus improve the activity of the current treatments. A second approach is to combine current immunotherapies with novel agents targeting complementary mechanisms. Identifying the appropriate novel agents may require different approaches than the traditional laboratory-based discovery work. For example, artificial intelligence-based research may help focusing the search for innovative and most promising combination partners. Conclusion Novel immunotherapies are needed in cancer patients with resistance to or relapse after current immunotherapeutic drugs. Such new treatments may include targeted agents or monoclonal antibodies to overcome the immune-suppressive tumor microenvironment. The mode of combining the novel treatments, including vaccines, needs to be matched to the patient’s immune status for achieving the maximum benefit. In this scenario, specific attention should be also paid nowadays to the immune intersection between COVID-19 and cancer.

Published
2021

27. Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe

Author

Oras, A., Quirant-Sanchez, B., Popadic, D., Thunberg, S., Winqvist, O., Heck, S., Cwikowski, M., Riemann, D., Seliger, B., Martinez Caceres, E., Uibo, R., Giese, T., Oras, A., Quirant-Sanchez, B., Popadic, D., Thunberg, S., Winqvist, O., Heck, S., Cwikowski, M., Riemann, D., Seliger, B., Martinez Caceres, E., Uibo, R., and Giese, T.

Abstract

A group of European FOCIS Centers of Excellence adapted panels of the Human Immunophenotyping Consortium (HIPC) for whole blood analysis. Using four core panels [T/regulatory T cell/B/natural killer (T/Treg/B/NK) and myeloid cells] the main leukocyte populations were analyzed in a clinical-diagnostic setting in a harmonized manner across different platforms. As a first step, the consortium presents here the absolute and relative frequencies of the leukocyte subpopulations in the peripheral blood of more than 300 healthy volunteers across six different European centers.

Published
2020

41. Abstract P4-06-01: Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial

Author

Massa, C, primary, Schneeweiss, A, additional, Karn, T, additional, Hanusch, CA, additional, Blohmer, J-U, additional, Fasching, PA, additional, Jackisch, C, additional, van Mackelenbergh, M, additional, Marmé, F, additional, Müller, V, additional, Schem, C, additional, Stickeler, E, additional, Huober, J, additional, Weber, KE, additional, Untch, M, additional, Denkert, C, additional, Loibl, S, additional, Mueller, A, additional, Biehl, K, additional, and Seliger, B, additional

Published
2019
Full Text
View/download PDF

45. 'Cancer Bio-Immunotherapy in Siena': Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015

Author

Maio, M., Bertocci, E., Fazio, C., Chiarucci, C., Cutaia, O., Scala, E., Giacobini, G., Lofiego, M. F., Fonsatti, E., Maccalli, C., Nicolay, H. J. M. G., Parmiani, G., Bronte, V., Seliger, B., Rivoltini, L., Sica, A., Squadrito, M. L., Rammensee, H. -G., Sahin, U., Schuler, G., Trajanoski, Z., Fridman, W. H., Marincola, F. M., Anichini, A., Calcinotto, A., Huber, S., Pozzi, C., Corna, G., Coulie, P., Figini, M., Calabrò, L., Ferrone, S., Buccione, C., Tagliamonte, M., Huber, C., Giordano, M., Astra Zeneca, R. I., Cuillerot, J. -M., Chartash, E., Azab, M., Colombo, M. P., Carbone, E., Martinoli, C., Nistico’, P., Garlanda, C., Di Giacomo, A. M., Straten, P. T., Oliveira, G., Moretta, L., Zuccolotto, G., Monfardini, S., and Nibit

Subjects
Cancer Research, Checkpoint blockade agents, business.industry, medicine.medical_treatment, Immunology, Cancer, Library science, Cancer vaccines, Immunotherapy, NIBIT, Targeted therapies, medicine.disease, Oncology, medicine, Immunology and Allergy, business
Published
2016

47. Abstracts from the 4th ImmunoTherapy of Cancer Conference

Author

Ženka, J., primary, Caisová, V., additional, Uher, O., additional, Nedbalová, P., additional, Kvardová, K., additional, Masáková, K., additional, Krejčová, G., additional, Paďouková, L., additional, Jochmanová, I., additional, Wolf, K. I., additional, Chmelař, J., additional, Kopecký, J., additional, Loumagne, L., additional, Mestadier, J., additional, D’agostino, S., additional, Rohaut, A., additional, Ruffin, Y., additional, Croize, V., additional, Lemaître, O., additional, Sidhu, S. S., additional, Althammer, S., additional, Steele, K., additional, Rebelatto, M., additional, Tan, T., additional, Wiestler, T., additional, Spitzmueller, A., additional, Korn, R., additional, Schmidt, G., additional, Higgs, B., additional, Li, X., additional, Shi, L., additional, Jin, X., additional, Ranade, K., additional, Koeck, S., additional, Amann, A., additional, Gamerith, G., additional, Zwierzina, M., additional, Lorenz, E., additional, Zwierzina, H., additional, Kern, J., additional, Riva, M., additional, Baert, T., additional, Coosemans, A., additional, Giovannoni, R., additional, Radaelli, E., additional, Gsell, W., additional, Himmelreich, U., additional, Van Ranst, M., additional, Xing, F., additional, Qian, W., additional, Dong, C., additional, Xu, X., additional, Guo, S., additional, Shi, Q., additional, Quandt, D., additional, Seliger, B., additional, Plett, C., additional, Amberger, D. C., additional, Rabe, A., additional, Deen, D., additional, Stankova, Z., additional, Hirn, A., additional, Vokac, Y., additional, Werner, J., additional, Krämer, D., additional, Rank, A., additional, Schmid, C., additional, Schmetzer, H., additional, Guerin, M., additional, Weiss, J. M., additional, Regnier, F., additional, Renault, G., additional, Vimeux, L., additional, Peranzoni, E., additional, Feuillet, V., additional, Thoreau, M., additional, Guilbert, T., additional, Trautmann, A., additional, Bercovici, N., additional, Doraneh-Gard, F., additional, Boeck, C. L., additional, Gunsilius, C., additional, Kugler, C., additional, Schmohl, J., additional, Kraemer, D., additional, Ismann, B., additional, Schmetzer, H. M., additional, Markota, A., additional, Ochs, C., additional, May, P., additional, Gottschlich, A., additional, Gosálvez, J. Suárez, additional, Karches, C., additional, Wenk, D., additional, Endres, S., additional, Kobold, S., additional, Hilmenyuk, T., additional, Klar, R., additional, Jaschinski, F., additional, Augustin, F., additional, Manzl, C., additional, Hoflehner, E., additional, Moser, P., additional, Zelger, B., additional, Köck, S., additional, Schäfer, G., additional, Öfner, D., additional, Maier, H., additional, Sopper, S., additional, Prado-Garcia, H., additional, Romero-Garcia, S., additional, Sandoval-Martínez, R., additional, Puerto-Aquino, A., additional, Lopez-Gonzalez, J., additional, Rumbo-Nava, U., additional, Van Hoylandt, A., additional, Busschaert, P., additional, Vergote, I., additional, Laengle, J., additional, Pilatova, K., additional, Budinska, E., additional, Bencsikova, B., additional, Sefr, R., additional, Nenutil, R., additional, Brychtova, V., additional, Fedorova, L., additional, Hanakova, B., additional, Zdrazilova-Dubska, L., additional, Allen, Chris, additional, Ku, Yuan-Chieh, additional, Tom, Warren, additional, Sun, Yongming, additional, Pankov, Alex, additional, Looney, Tim, additional, Hyland, Fiona, additional, Au-Young, Janice, additional, Mongan, Ann, additional, Becker, A., additional, Tan, J. B. L., additional, Chen, A., additional, Lawson, K., additional, Lindsey, E., additional, Powers, J. P., additional, Walters, M., additional, Schindler, U., additional, Young, S., additional, Jaen, J. C., additional, Yin, S., additional, Chen, Y., additional, Gullo, I., additional, Gonçalves, G., additional, Pinto, M. L., additional, Athelogou, M., additional, Almeida, G., additional, Huss, R., additional, Oliveira, C., additional, Carneiro, F., additional, Merz, C., additional, Sykora, J., additional, Hermann, K., additional, Hussong, R., additional, Richards, D. M., additional, Fricke, H., additional, Hill, O., additional, Gieffers, C., additional, Pinho, M. P., additional, Barbuto, J. A. M., additional, McArdle, S. E., additional, Foulds, G., additional, Vadakekolathu, J. N., additional, Abdel-Fatah, T. M. A., additional, Johnson, C., additional, Hood, S., additional, Moseley, P., additional, Rees, R. C., additional, Chan, S. Y. T., additional, Pockley, A. G., additional, Rutella, S., additional, Geppert, C., additional, Hartmann, A., additional, Kumar, K. Senthil, additional, Gokilavani, M., additional, Wang, S., additional, Redondo-Müller, M., additional, Heinonen, K., additional, Marschall, V., additional, Thiemann, M., additional, Zhang, L., additional, Mao, B., additional, Jin, Y., additional, Zhai, G., additional, Li, Z., additional, Wang, Z., additional, An, X., additional, Qiao, M., additional, Zhang, J., additional, Weber, J., additional, Kluger, H., additional, Halaban, R., additional, Sznol, M., additional, Roder, H., additional, Roder, J., additional, Grigorieva, J., additional, Asmellash, S., additional, Meyer, K., additional, Steingrimsson, A., additional, Blackmon, S., additional, Sullivan, R., additional, Sutanto, W., additional, Guenther, T., additional, Schuster, F., additional, Salih, H., additional, Babor, F., additional, Borkhardt, A., additional, Kim, Y., additional, Oh, I., additional, Park, C., additional, Ahn, S., additional, Na, K., additional, Song, S., additional, Choi, Y., additional, Poprach, A., additional, Lakomy, R., additional, Selingerova, I., additional, Demlova, R., additional, Kozakova, S., additional, Valik, D., additional, Petrakova, K., additional, Vyzula, R., additional, Aguilar-Cazares, D., additional, Galicia-Velasco, M., additional, Camacho-Mendoza, C., additional, Islas-Vazquez, L., additional, Chavez-Dominguez, R., additional, Gonzalez-Gonzalez, C., additional, Lopez-Gonzalez, J. S., additional, Yang, S., additional, Moynihan, K. D., additional, Noh, M., additional, Bekdemir, A., additional, Stellacci, F., additional, Irvine, D. J., additional, Volz, B., additional, Kapp, K., additional, Oswald, D., additional, Wittig, B., additional, Schmidt, M., additional, Kleef, R., additional, Bohdjalian, A., additional, McKee, D., additional, Moss, R. W., additional, Saeed, Mesha, additional, Zalba, Sara, additional, Debets, Reno, additional, ten Hagen, Timo L. M., additional, Javed, S., additional, Becher, J., additional, Koch-Nolte, F., additional, Haag, F., additional, Gordon, E. M., additional, Sankhala, K. K., additional, Stumpf, N., additional, Tseng, W., additional, Chawla, S. P., additional, Suárez, N. González, additional, Báez, G. Bergado, additional, Rodríguez, M. Cruz, additional, Pérez, A. Gutierrez, additional, García, L. Chao, additional, Fernández, D. Hernández, additional, Pous, J. Raymond, additional, Ramírez, B. Sánchez, additional, Jacoberger-Foissac, C., additional, Saliba, H., additional, Seguin, C., additional, Brion, A., additional, Frisch, B., additional, Fournel, S., additional, Heurtault, B., additional, Otterhaug, T., additional, Håkerud, M., additional, Nedberg, A., additional, Edwards, V., additional, Selbo, P., additional, Høgset, A., additional, Jaitly, T., additional, Dörrie, J., additional, Schaft, N., additional, Gross, S., additional, Schuler-Thurner, B., additional, Gupta, S., additional, Taher, L., additional, Schuler, G., additional, Vera, J., additional, Rataj, F., additional, Kraus, F., additional, Grassmann, S., additional, Chaloupka, M., additional, Lesch, S., additional, Heise, C., additional, Cadilha, B. M. Loureiro, additional, and Dorman, K., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results